Élodie Beaumont

967 total citations
22 papers, 776 citations indexed

About

Élodie Beaumont is a scholar working on Epidemiology, Hepatology and Virology. According to data from OpenAlex, Élodie Beaumont has authored 22 papers receiving a total of 776 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Epidemiology, 16 papers in Hepatology and 6 papers in Virology. Recurrent topics in Élodie Beaumont's work include Hepatitis C virus research (15 papers), Hepatitis B Virus Studies (12 papers) and HIV Research and Treatment (6 papers). Élodie Beaumont is often cited by papers focused on Hepatitis C virus research (15 papers), Hepatitis B Virus Studies (12 papers) and HIV Research and Treatment (6 papers). Élodie Beaumont collaborates with scholars based in France, Germany and Finland. Élodie Beaumont's co-authors include Philippe Roingeard, Denys Brand, Julien Burlaud‐Gaillard, Jean‐Christophe Meunier, Charline Miot, Yves Delneste, Pascale Jeannin, Helmut Fickenscher, Romuald Patient and Laurence Preisser and has published in prestigious journals such as Journal of Biological Chemistry, Gastroenterology and PLoS ONE.

In The Last Decade

Élodie Beaumont

21 papers receiving 769 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Élodie Beaumont France 13 343 337 299 163 124 22 776
Andreas R. Kammer Switzerland 12 346 1.0× 387 1.1× 335 1.1× 117 0.7× 94 0.8× 13 793
Benno Grabscheid Switzerland 9 316 0.9× 448 1.3× 226 0.8× 84 0.5× 91 0.7× 11 682
Liam J. Fanning Ireland 20 564 1.6× 684 2.0× 290 1.0× 127 0.8× 108 0.9× 57 1.1k
Amanda Goodsell United States 11 289 0.8× 125 0.4× 315 1.1× 136 0.8× 102 0.8× 19 688
Malika Ait‐Goughoulte France 17 788 2.3× 655 1.9× 217 0.7× 57 0.3× 111 0.9× 25 1.1k
Rongjuan Pei China 20 464 1.4× 403 1.2× 216 0.7× 71 0.4× 158 1.3× 36 866
Yoshiyuki Nagai Japan 9 200 0.6× 124 0.4× 204 0.7× 116 0.7× 85 0.7× 12 518
Lars Erdtmann France 8 313 0.9× 148 0.4× 337 1.1× 504 3.1× 223 1.8× 8 881
Susan Smyk‐Pearson United States 8 336 1.0× 258 0.8× 733 2.5× 90 0.6× 132 1.1× 8 994
Elizabeth J. Elrod United States 12 207 0.6× 231 0.7× 140 0.5× 41 0.3× 123 1.0× 17 620

Countries citing papers authored by Élodie Beaumont

Since Specialization
Citations

This map shows the geographic impact of Élodie Beaumont's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Élodie Beaumont with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Élodie Beaumont more than expected).

Fields of papers citing papers by Élodie Beaumont

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Élodie Beaumont. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Élodie Beaumont. The network helps show where Élodie Beaumont may publish in the future.

Co-authorship network of co-authors of Élodie Beaumont

This figure shows the co-authorship network connecting the top 25 collaborators of Élodie Beaumont. A scholar is included among the top collaborators of Élodie Beaumont based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Élodie Beaumont. Élodie Beaumont is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Roingeard, Philippe, et al.. (2023). Current Hepatitis C Vaccine Candidates Based on the Induction of Neutralizing Antibodies. Viruses. 15(5). 1151–1151. 11 indexed citations
2.
Burlaud‐Gaillard, Julien, et al.. (2021). Incorporation of apolipoprotein E into HBV–HCV subviral envelope particles to improve the hepatitis vaccine strategy. Scientific Reports. 11(1). 21856–21856. 9 indexed citations
3.
Beaumont, Élodie, Laurence Preisser, Charline Miot, et al.. (2021). IL-26 inhibits hepatitis C virus replication in hepatocytes. Journal of Hepatology. 76(4). 822–831. 11 indexed citations
4.
Beaumont, Élodie, et al.. (2020). Mixing particles from various HCV genotypes increases the HBV‐HCV vaccine ability to elicit broadly cross‐neutralizing antibodies. Liver International. 40(8). 1865–1871. 6 indexed citations
5.
Roingeard, Philippe & Élodie Beaumont. (2020). Hepatitis C Vaccine: 10 Good Reasons for Continuing. Hepatology. 71(5). 1845–1850. 24 indexed citations
6.
Miot, Charline, Caroline Poli, Élodie Beaumont, et al.. (2019). IL-26, a Cytokine With Roles in Extracellular DNA-Induced Inflammation and Microbial Defense. Frontiers in Immunology. 10. 204–204. 60 indexed citations
7.
Dusséaux, Mathilde, Guillemette Masse‐Ranson, Sylvie Darche, et al.. (2017). Viral Load Affects the Immune Response to HBV in Mice With Humanized Immune System and Liver. Gastroenterology. 153(6). 1647–1661.e9. 57 indexed citations
8.
9.
Beaumont, Élodie, et al.. (2016). Hepatitis C Virus E1 and E2 Proteins Used as Separate Immunogens Induce Neutralizing Antibodies with Additive Properties. PLoS ONE. 11(3). e0151626–e0151626. 12 indexed citations
10.
11.
Passot, Christophe, Christophe Arnoult, Élodie Beaumont, et al.. (2015). The neonatal Fc receptor does not modulate hepatitis C virus neutralization. Journal of General Virology. 96(5). 1062–1066. 4 indexed citations
12.
Miot, Charline, Élodie Beaumont, Dorothée Duluc, et al.. (2014). IL-26 is overexpressed in chronically HCV-infected patients and enhances TRAIL-mediated cytotoxicity and interferon production by human NK cells. Gut. 64(9). 1466–1475. 50 indexed citations
13.
Beaumont, Élodie & Philippe Roingeard. (2014). Vers un vaccin prophylactique bivalent contre les virus des hépatites B et C ?. médecine/sciences. 30(1). 33–35.
14.
Beaumont, Élodie, et al.. (2014). The Association of Hepatitis C Virus Glycoproteins with Apolipoproteins E and B Early in Assembly Is Conserved in Lipoviral Particles. Journal of Biological Chemistry. 289(27). 18904–18913. 69 indexed citations
15.
Tartour, Kévin, Julien Burlaud‐Gaillard, Xuan-Nhi Nguyen, et al.. (2014). IFITM proteins are incorporated onto HIV-1 virion particles and negatively imprint their infectivity. Retrovirology. 11(1). 103–103. 105 indexed citations
16.
Preisser, Laurence, Charline Miot, Hélène Le Guillou‐Guillemette, et al.. (2014). IL‐34 and macrophage colony‐stimulating factor are overexpressed in hepatitis C virus fibrosis and induce profibrotic macrophages that promote collagen synthesis by hepatic stellate cells. Hepatology. 60(6). 1879–1890. 106 indexed citations
17.
Beaumont, Élodie & Philippe Roingeard. (2013). Prospects for prophylactic hepatitis C vaccines based on virus-like particles. Human Vaccines & Immunotherapeutics. 9(5). 1112–1118. 13 indexed citations
18.
Monel, Blandine, et al.. (2012). HIV Cell-to-Cell Transmission Requires the Production of Infectious Virus Particles and Does Not Proceed through Env-Mediated Fusion Pores. Journal of Virology. 86(7). 3924–3933. 51 indexed citations
19.
Beaumont, Élodie, Romuald Patient, Christophe Hourioux, Isabelle Dimier‐Poisson, & Philippe Roingeard. (2012). Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine. Hepatology. 57(4). 1303–1313. 51 indexed citations
20.
Lejeune, Ferdinand, et al.. (1973). Growth inhibitory effect of peritoneal macrophages on Harding Passey melanoma, its impairment by macrophage lysosome overloading. British Journal of Cancer. 28(1). 80–80. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andreas R. Kammer Breakdown of academic impact, for papers by Benno Grabscheid Breakdown of academic impact, for papers by Liam J. Fanning Breakdown of academic impact, for papers by Amanda Goodsell Breakdown of academic impact, for papers by Malika Ait‐Goughoulte Breakdown of academic impact, for papers by Rongjuan Pei Breakdown of academic impact, for papers by Yoshiyuki Nagai Breakdown of academic impact, for papers by Lars Erdtmann Breakdown of academic impact, for papers by Susan Smyk‐Pearson Breakdown of academic impact, for papers by Elizabeth J. Elrod
Rankless by CCL
2026